Use of botulinum toxin in small-angle heterotropia and decompensating heterophoria: A review of the literature

Strabismus

Volumn 15, Issue 3, 2007, Pages 165-171

  Ripley, L ^a,c   Rowe, F J ^b  

^a DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Northern Lincolnshire and Goole Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

Botulinum toxin; Decompensating heterophoria; Esophoria; Esotropia; Exophoria; Exotropia; Small angle heterotropia

Indexed keywords

BOTULINUM TOXIN; KETAMINE; LOCAL ANESTHETIC AGENT;

ABDUCENS NERVE PARALYSIS; ACUTE DISEASE; AMBLYOPIA; BINOCULAR VISION; CONJUNCTIVAL HEMORRHAGE; CONVERGENT STRABISMUS; CORNEA ULCER; DECOMPENSATING HETEROPHORIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DIVERGENT STRABISMUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EYE SURGERY; FACE MUSCLE; HUMAN; INFORMATION RETRIEVAL; KERATITIS; MEDICAL LITERATURE; MEDLINE; MUSCLE SPASM; NYSTAGMUS; OSCILLOPSIA; PARALYSIS; PERFORATING EYE INJURY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PTOSIS; RETROBULBAR HEMORRHAGE; REVIEW; SMALL ANGLE HETEROTROPIA; STRABISMUS; SURGICAL ERROR; SURGICAL RISK; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

BOTULINUM TOXINS; ESOTROPIA; EXOTROPIA; HUMANS;

EID: 34548348763     PISSN: 09273972     EISSN: 17445132     Source Type: Journal    
DOI: 10.1080/09273970701506094     Document Type: Review

References (32)

1. Abbasoglu E, Sener E, Sanac A. Factors influencing success and dose-effect relation of Botulinum A treatment. Eye. 1996;10:385-391.
2. Bernstein J, Lee J. Botulinum toxin: An alternative to surgery in symptomatic exodeviations. Br Orthoptic J. 1990;47:31-38.
3. Biglan A, Burnstine R, Rogers G, Saunders R. Management of strabismus with botulinum A toxin. Ophthalmology. 1989;96:935-943.
4. Campos EC, Schiavi C, Bellusci C. Critical age of botulinum toxin treatment in essential infantile esotropia. J Pediatr Ophthalmol Strabismus. 2000;37:328-332.
5. Dawson EL, Marshman WE, Adams GG. The role of botulinum toxin A in acute-onset esotropia. Ophthalmology. 1999a;106:1727-1730.
6. Dawson EL, Marshman W, Lee J. Role of botulinum toxin in surgically over-corrected exotropia. J AAPOS. 1999b;3:269-271.
7. Dawson ELM, Sainari A, Lee JP. Does botulinum toxin have a role in the treatment of secondary strabismus? Trans 29th Eur Strabismol Assoc., Turkey, 2004;53-54.
8. Horgan S, Lee J, Bunce C. The long term use of botulinum toxin for adult strabismus. J Pediatr Ophthalmol Strabismus. 1998;35:9-16.
9. Kerr NC, Hoehn MB. Botulinum toxin for sixth nerve palsies in children with brain tumors. J Am Acad Pediatr Ophthalmol Strabismus. 2001;5:21-25.
10. Ketley M, Powell C, Lee J, Elston J. Botylinum toxin adaption test: use of botulinum in the investigation of the sensory state in strabismus. In: Orthoptic Horizons. Trans Sixth Int Orthoptic Congr. London: British Orthoptic Society, Harrogate, 1987;289-293.
11. Lawson J, Kousoulides L, Lee J. Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin. J AAPOS. 1998;2(4):195-200.
12. Lee J. Botulinum toxin in the management of ocular muscle disorders. Am Orthoptic J. 1995;45:109-125.
13. Lee J, Elston J, Vickers S, et al. Botulinum toxin therapy for squint. Eye. 1988;2:24-28.
14. Lennerstrand G, Asmund Nordbo O, Tian S, Erikson-Derouet B, Ali T. Treatment of strabismus and nystagmus with botulinum toxin type A. Acta Ophthalmol Scand. 1998;76:27-37.
15. Lymburn E, MacEwen C. Botulinum toxin in the management of heterophoria. Br Orthoptic J. 1994;51:38-40.
16. Lymburn E, MacEwen C. Diagnostic applications of botulinum toxin. Sensory status of patients with strabismus. Br Orthoptic J. 1998;55:45-47.
17. Magoon E, Scott A. Botulinum toxin chemo-denervation in infants and children: an alternative to incisional strabismus surgery. J Pediatr Ophthalmol Strabismus. 1987;110:719-722.
18. Marsh IB. Is botulinum toxin treatment useful in decompensating microtropias? Trans 26th Eur Strabismol Assoc., Barcelona, 2000;83-85.
19. McNeer K. An investigation of the clinical use of botulinum toxin A as a post-operative adjustment procedure in the therapy of strabismus. J Pediatr Ophthalmol Strabismus. 1990;27:3-9.
20. McNeer KW, Tucker MG, Guerry CH, Spencer RF. Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J Pediatr Ophthalmol Strabismus. 2003;40:288-292.
21. Powell C, Lee J, Elston J. Role of botulinum toxin in the treatment of squint-current indications. Br Orthoptic J. 1987;44:28-33.
22. Rayner SA, Hollick EJ, Lee JP. Botulinum toxin in childhood strabismus. Strabismus. 1999;7:103-111.
23. Rosenbaum A. The current use of botulinum toxin therapy in strabismus. Arch Ophthalmol. 1996;114:213-215.
24. Rowe F, Noonan C, Nayak H. Use of botulinum toxin in pre-adolescent children. Trans 10th Int Orthoptic Congr. 2004;CD-ROM 187704024x.
25. Rowe FJ, Noonan CP, Nayak H. Botulinum toxin as a treatment option for decompensating intermittent strabismus in children. Trans 30th Eur Strabismol Assoc., Killarney, Ireland, 2005;101-104.
26. Sabetti L, D'Alessandri L, Salvatori K, Balestrazzi E. The use of botulinum toxin type A in the treatment of chronic sixth ocular nerve palsy. Trans 28th Eur Strabismol Assoc., Bergen, 2003;191-192.
27. Scott A. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79:734-770.
28. Scott A, Magoon E, McNeer K, Stager D. Botulinum treatment of childhood strabismus. Ophthalmology. 1990;97:1434-1438.
29. Sener E, Sanac A. Efficacy and complications of dose increments of botulinum toxin-A in the treatment of horizontal comitant strabismus. Eye. 2000;14:873-878.
30. Spencer RF, Tucker MG, Choi RY, McNeer KW. Botulinum toxin management of childhood intermittent exotropia. Ophthalmology. 1997;104:1762-1767.
31. Tejedor J, Rodriguez J. Retreatment of children after surgery for acquired esotropia: reoperation versus botulinum toxin injection. Br J Ophthalmol. 1998;82:110-114.
32. Tejedor J, Rodriguez JM. Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin. Invest Ophthalmol Vis Sci. 2001;42:2542-2546.